Fate Therapeutics - Stock Price History | FATE

Historical daily share price chart and data for Fate Therapeutics since 2021 adjusted for splits. The latest closing stock price for Fate Therapeutics as of September 24, 2021 is 64.85.
  • The all-time high Fate Therapeutics stock closing price was 117.40 on January 14, 2021.
  • The Fate Therapeutics 52-week high stock price is 121.16, which is 86.8% above the current share price.
  • The Fate Therapeutics 52-week low stock price is 37.89, which is 41.6% below the current share price.
  • The average Fate Therapeutics stock price for the last 52 weeks is 78.85.
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Fate Therapeutics Historical Annual Stock Price Data
Year Average Stock Price Year Open Year High Year Low Year Close Annual % Change
2020 38.1605 19.4700 100.9500 17.2800 90.9300 364.64%
2019 17.2276 13.5300 22.5000 13.1500 19.5700 52.53%
2018 11.6048 6.3000 16.9800 6.3000 12.8300 109.98%
2017 3.8386 2.6900 6.6400 2.6000 6.1100 143.43%
2016 2.2444 3.2900 3.5400 1.4918 2.5100 -25.52%
2015 5.4974 5.1400 7.9300 3.2700 3.3700 -33.00%
2014 6.2189 6.3600 12.2800 3.5800 5.0300 -19.90%
2013 6.2960 6.6200 8.5000 4.6100 6.2800 0.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $6.554B $0.031B
Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $134.727B 8.97
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.500B 21.17
Biohaven Pharmaceutical Holding (BHVN) United States $8.865B 0.00
Emergent Biosolutions (EBS) United States $2.891B 6.97
Arcus Biosciences (RCUS) United States $2.641B 0.00
Myovant Sciences (MYOV) United Kingdom $2.145B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.998B 0.00
Zymeworks (ZYME) Canada $1.380B 0.00
Ambrx Biopharma (AMAM) United States $0.521B 0.00
SQZ Biotechnologies (SQZ) United States $0.427B 0.00
Enzo Biochem (ENZ) United States $0.175B 51.71